Sol-gel acquires patidegib, a phase 3, fda-breakthrough-designated orphan product candidate to pursue potential market of over $300 million

Ness ziona, israel, jan. 27, 2023 (globe newswire) --  sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company with fda approvals for epsolay® and twyneo®, two innovative dermatology products that were launched in the u.s. by partner galderma during 2022, announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of gorlin syndrome from pellepharm, inc. gorlin syndrome is a rare disease with no currently approved therapies by the u.s. food and drug administration (fda) or european medical association (ema). sol-gel broadens its pipeline with this new chemical entity, designated as investigational compound sgt-610, which has the potential to be the first-ever drug for treatment of gorlin syndrome. sol-gel expects the transaction to close on or about january 30, 2023, subject to the satisfaction of customary closing conditions.
SLGL Ratings Summary
SLGL Quant Ranking